



331 Treble Cove Road
North Billerica, MA 01862

800.362.2668
www.lantheus.com

April 3, 2014

VIA ELECTRONIC MAIL

LEU TechneLite® Technetium Tc99m Generator Certification

Lantheus Medical Imaging hereby attests that **West Coast Nuclear Pharmacy in Tampa, Florida** is currently purchasing an LEU TechneLite® Technetium Tc99m Generator weekly.

Lantheus received FDA approval for the commercial use of Low-Enriched Uranium (LEU) in 2010 and has used a blend of Highly Enriched Uranium (HEU) and LEU Mo-99 in its TechneLite® generators in the U.S. market since 2011. This is the first Tc-99m generator in the United States that contains at least 95 percent non-HEU-sourced molybdenum-99 (Mo-99) that meets the Centers for Medicare and Medicaid Services criteria for the incremental add-on HOPPS reimbursement.

With the introduction of our LEU TechneLite® generator for use in connection with nuclear imaging procedures, Lantheus fully supports the United States government's global nuclear security strategy to encourage reliable supplies of medical radioisotopes produced from non-HEU sources. On January 2, 2013, President Obama signed into law the American Medical Isotopes Production Act of 2011 (AMIPA) as part of the 2013 National Defense Authorization Act. The AMIPA encourages the domestic production of LEU Mo-99 and provides for the eventual prohibition of the export of HEU from the United States.

The company's LEU and HEU-produced TechneLite® generators are equivalent in performance and use as recognized by FDA approval of LEU-produced Mo-99 generators. The only difference between the LEU TechneLite® generator and the standard TechneLite® generator is that LEU TechneLite® is produced using Mo-99 sourced from at least 95 percent LEU instead of HEU.

This certification is valid for **90** days.

Attested on this day April 3, 2014 by:

A handwritten signature in black ink that reads "Melissa Layman".

Melissa Layman
Vice President, Global Marketing
Lantheus Medical Imaging, Inc.

cc: Kathleen D. McFadden, Director, Sales and Operations
Michael P. Duffy, General Counsel